Business Context and Reporting Period
This Form 8-K is a current report filed by NeuroBo Pharmaceuticals, Inc. (not Metavia Inc.) on June 29, 2023, regarding events occurring on June 28, 2023. The filing details the results of the Company's Annual Meeting of Stockholders and the adoption of a new director compensation policy.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on corporate governance matters and voting results.
Material Changes and Voting Results
At the Annual Meeting held on June 28, 2023, 19,383,746 shares were represented (71.2% of the 27,241,685 outstanding shares). Stockholders approved the following proposals:
- Proposal 1 (Director Election): Elected Na Yeon (Irene) Kim and D. Gordon Strickland as Class I directors for three-year terms.
- Proposal 2 (Auditor Ratification): Ratified the appointment of BDO USA, LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2023.
- Proposal 3 (Reverse Stock Split): Approved an amendment to the Certificate of Incorporation to effect a reverse split of outstanding common stock at a ratio between 1-for-5 and 1-for-8, to be determined by the Board.
- Proposal 4 (Adjournment Authority): Authorized adjournments to solicit additional proxies if necessary to approve the reverse split.
Management Commentary and New Policies
The Board approved an Amended and Restated Non-Employee Director Compensation Policy, effective June 27, 2023, to attract and retain qualified directors. Key terms include:
- Cash Retainers: Base Board Retainer of $40,000 annually, with additional fees for committee chairs and members ranging from $5,000 to $35,000.
- Equity Grants:
- Legacy Grant: 87,500 RSUs for directors serving continuously through 2022.
- Initial Grant: 25,000 RSUs for new directors appointed in 2023.
- Annual Grant: 12,500 RSUs for directors at each subsequent annual meeting.
- Compensation Limits: Total annual compensation for any non-employee director is capped at $750,000, or $1,500,000 for directors joining during the fiscal year.
Investor Verification Checklist
- Verify the specific reverse stock split ratio (1-for-5 to 1-for-8) once determined by the Board.
- Confirm the implementation date and share count impact of the reverse split on Nasdaq.
- Review the full text of the Amended and Restated Non-Employee Director Compensation Policy (Exhibit 10.1) for detailed vesting schedules.
- Monitor future filings for the appointment of the new Class I directors and their committee assignments.